Fili M, et al. - Investigators studied 317 participants to assess the ocular as well as the patient survival in thicker tumors treated with γ-emitting iodine-125 (¹²⁵I) and β-emitting ruthenium-106 (¹⁰⁶Ru). A significantly higher rate of repeated brachytherapy was reported among those treated with ¹⁰⁶Ru (8%) when compared with ¹²⁵I. They observed similar Kaplan-Meier disease-specific and relative 10-year survival in matched groups of 5.5–7.4 mm (relative survival ¹⁰⁶Ru 59%, ¹²⁵I 56%) and ≥7.5 mm thick tumors (relative survival ¹⁰⁶Ru 46%, ¹²⁵I 44%). Overall, they concluded rates of enucleation or patient survival were not significantly different.